Chief Scientific Officer: Gavin P. Robertson, PhD
Gavin P. Robertson, Ph.D. is Professor of Pharmacology, Pathology, Dermatology and Surgery at Penn State University, Director, Penn State Melanoma Center, and Director, Foreman Foundation Melanoma Research Laboratory in the Department of Pharmacology and Penn State Cancer Institute. His research focuses on malignant melanoma; the most deadly form of skin cancer, with the goal of unraveling the biology and signaling pathways involved in melanoma tumor development, and in developing the next generation of therapeutic agents to treat this disease. The discovery of Akt3 involvement in ~70% of human melanomas led to the development of ISC-4, which targets Akt3 signaling. Nanotechnology and bioengineering are enabling the use of nanoliposomes and ultrasound that deliver therapeutic products into melanoma cells, leading to the development of Nanolipolee-007. His translational research program is focused on developing better therapeutics based on the biology of the disease. He holds a Ph.D., University of California, Riverside, and completed his Postdoctoral Training at the Ludwig Institute for Cancer Research in San Diego.
Chief Medical Officer: Rogerio I. Neves, MD, PhD
Rogerio I. Neves, MD, PhD, is Professor of Surgery, Dermatology, Pharmacology and Medicine at Penn State University College of Medicine in Hershey, PA. He is Deputy Director of the Penn State Hershey Melanoma Center, and clinical science leader of the Melanoma Therapeutics Program, and Director of the Skin Oncology Program of the Penn State Cancer Institute. He received his medical degree from Faculdade de Medicina do ABC in Sao Paulo, Brazil. He completed residencies in general and plastic and reconstructive surgery. He completed research fellowships at Penn State University College of Medicine, and at Memorial Sloan-Kettering Cancer Center in New York, NY, and a PhD in medicine (surgery) at the University of Sao Paulo. He is a member of the American and Brazilian Society of Plastic Surgery, the American Society of Clinical Oncology, American College of Surgeons and International Dermoscopy Society, the Society for Melanoma Research, among others. In addition, he serves on several university and hospital related committees. Dr. Neves has received numerous grants for scientific and clinical research studies. Co-editor of a textbook on dermoscopy and co-author of various textbook chapters. His work has been widely published in peer reviewed journals, and he serves on the editorial board of 3 medical journals. He is a frequent invited lecturer as well as a presenter at national and international medical and scientific meetings around the world.
Chief Commercial Advisor & Director: Shawn Patrick O’Brien
A biotech and big pharma executive leader with 30 years experience in building highly successful global enterprises. Shawn has extensive international experience in business development, marketing, selling, licensing, researching & developing both small and large molecules, with block buster sales results.
Mr. O'Brien is one of the 3 founders of AltheRx Pharmaceuticals, and served as President and CEO for 3 years where he built the business and secured funding to acquire and develop a mid-stage asset from GSK. He further developed the asset to be Phase 3 ready for Overactive Bladder.
Mr. O'Brien was President and CEO of Profectus BioSciences Inc. a R&D company focused on treating and preventing chronic viral infections that lead to cancer. He secured equity financing and a major vaccine licensing deal with Wyeth that led to over $100 million in government funding for the Profectus BioSciences emerging portfolio.
Prior to joining Profectus, he was President and CEO of Solstice Neurosciences Inc, where they secured $125 Million in private financing and over $35 Million in upfront deal income. The business was sold to US World Meds.
Previously he held executive positions with AstraZeneca Pharmaceuticals, most recently as Vice President of commercial operations for emerging brands. Prior to that, he led AstraZeneca's Business Unit for the Respiratory & Inflammation and commercial leader for the Oncology therapeutic area, each having in excess of $1 billion in sales.
He is Chairman of Cyrano, LLC which develops botulinum toxin for Rhinitis. Shawn is a Board member of the Chester Keystone Health System, a 5 member non-profit hospital group in the greater Philadelphia area and also serves on the finance, audit & governance committees. He is a Co-Chair of the Hubert Schoemaker Classic, which raises over $500,000 each year for Melmark, a non-profit institution which provides programs for children and adults with neurological developmental disabilities. Shawn is also an Advisory Board member of the Greater Philadelphia Life Sciences Congress. He is a founding partner of Key BioPharma Partners, LLC.